{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:zifanocycline [INN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
INN:atinvicitinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:sucunamostat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:Dalzanemdor [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:obeldesivir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02284919: Phase 1 Interventional Active, not recruiting Breast Cancer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
ISO-1 F-18 is a benzamide analog radiolabeled with 18F. It is a sigma-2 receptor ligand. Since sigma-2 receptor is expressed in higher density in proliferating tumor cells versus quiescent tumor cells, ISO-1 F-18 can be used as a positron emission tomography (PET) tracer to evaluate tumor proliferation by PET in patients with malignant neoplasms. Currently, ISO-1 F-18 in Phase I clinical trial as an investigational radiotracer in primary breast cancer.
Status:
Investigational
Source:
NCT03692234: Not Applicable Interventional Recruiting Deficiency; Diet
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
